Zoetis (NYSE:ZTS) Raised to “Hold” at The Goldman Sachs Group

Zoetis (NYSE:ZTS) was upgraded by stock analysts at The Goldman Sachs Group to a “hold” rating in a note issued to investors on Friday, Zacks reports.

ZTS has been the topic of several other research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Zoetis in a research report on Wednesday, September 9th. HSBC cut their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Citigroup reduced their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. UBS Group decreased their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Finally, Zacks Research cut shares of Zoetis from a “hold” rating to a “strong sell” rating in a research note on Monday, August 10th. Seven research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $99.14.

Zoetis Trading Up 1.1%

NYSE ZTS traded up $0.89 on Friday, reaching $79.31. 5,570,530 shares of the company were exchanged, compared to its average volume of 4,418,894. The business’s fifty day moving average price is $74.03 and its 200 day moving average price is $83.49. The stock has a market capitalization of $32.77 billion, a P/E ratio of 13.07, a price-to-earnings-growth ratio of 1.85 and a beta of 0.74. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. Zoetis has a fifty-two week low of $68.77 and a fifty-two week high of $148.30.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The business had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period last year, the company earned $1.76 EPS. The company’s revenue for the quarter was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts forecast that Zoetis will post 6.15 earnings per share for the current year.

Institutional Investors Weigh In On Zoetis

A number of institutional investors have recently modified their holdings of ZTS. V Square Quantitative Management LLC grew its holdings in shares of Zoetis by 8.0% in the third quarter. V Square Quantitative Management LLC now owns 16,854 shares of the company’s stock valued at $1,177,000 after purchasing an additional 1,254 shares in the last quarter. Moody National Bank Trust Division lifted its holdings in Zoetis by 108.5% during the 3rd quarter. Moody National Bank Trust Division now owns 15,927 shares of the company’s stock worth $1,112,000 after buying an additional 8,288 shares in the last quarter. Rockland Trust Co. lifted its holdings in Zoetis by 19.8% during the 3rd quarter. Rockland Trust Co. now owns 244,065 shares of the company’s stock worth $17,043,000 after buying an additional 40,294 shares in the last quarter. State Street Corp boosted its position in Zoetis by 1.8% in the 2nd quarter. State Street Corp now owns 19,667,723 shares of the company’s stock valued at $1,413,323,000 after buying an additional 343,322 shares during the period. Finally, Tidal Investments LLC boosted its position in Zoetis by 22.8% in the 2nd quarter. Tidal Investments LLC now owns 493,507 shares of the company’s stock valued at $35,463,000 after buying an additional 91,492 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostics and other products for pets and livestock. Its portfolio is designed to help prevent and treat disease, improve animal health and support veterinary care.

The company serves the companion animal market with products for dogs, cats and other pets, including parasiticides, vaccines, dermatology treatments and pain-management therapies. Zoetis also provides animal health products for cattle, swine, poultry, fish and other livestock, along with diagnostic instruments, tests and services used by veterinarians and producers.

Zoetis was established as an independent public company in 2013 after being separated from Pfizer, which had operated the business as Pfizer Animal Health.